85.74

1.10% -0.93

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $85.74, with a volume of 7.79M. It is down -1.10% in the last 24 hours and down -7.63% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Previous Close:

$86.67

Open:

$86.65

24h Volume:

7.79M

Relative Volume:

0.65

Market Cap:

$149.45B

Revenue:

$45.13B

Net Income/Loss:

$6.28B

P/E Ratio:

23.89

EPS:

3.5895

Net Cash Flow:

$7.38B

1W Performance:

-3.02%

1M Performance:

-7.63%

6M Performance:

-33.32%

1Y Performance:

-35.52%

1-Day Range:

$84.96

$86.84

1-Week Range:

$84.96

$88.84

52-Week Range:

$81.97

$139.06

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1111)

Industry

Medical Devices (142)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

115,000

Twitter

@AbbottNews

Next Earnings Date

2026-07-16

Latest SEC Filings

ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABT Abbott Laboratories	85.80	150.96B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	306.64	119.99B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	75.92	99.63B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	50.38	85.67B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.55	50.41B	6.30B	1.07B	1.09B	1.8406

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-22-26	Downgrade	Daiwa Securities	Outperform → Neutral
Oct-10-25	Initiated	The Benchmark Company	Buy
Jul-18-25	Upgrade	Jefferies	Hold → Buy
Jun-16-25	Initiated	Leerink Partners	Market Perform
Oct-08-24	Initiated	Oppenheimer	Outperform
Sep-19-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Downgrade	Edward Jones	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

01:47 AM

10 Dividend Growth Stocks To Guard Wealth - Sure Dividend

01:47 AM

11:02 AM

Abbott Labs Settles Illinois Medical History Privacy Lawsuit - Bloomberg Law News

11:02 AM

09:32 AM

Abbott (ABT) Launches Innovative Dual Glucose-Ketone Monitoring System - GuruFocus

09:32 AM

09:27 AM

Abbott Laboratories stock (US0028241000): investors weigh diagnostics and growth drivers - AD HOC NEWS

09:27 AM

09:20 AM

Abbott secures CE mark for dual glucose-ketone sensor By Investing.com - Investing.com Canada

09:20 AM

09:08 AM

Abbott wins CE mark for dual glucose-ketone sensor - Drug Delivery Business

09:08 AM

09:00 AM

New Abbott sensor tracks glucose and ketones to flag DKA risk - Stock Titan

09:00 AM

08:46 AM

How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026 - TradingView

08:46 AM

07:34 AM

Abbott (ABT) Sees Cologuard and Cologuard Plus Confirmed in Upda - GuruFocus

07:34 AM

07:01 AM

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening - PR Newswire

07:01 AM

May 26, 2026

Abbott Laboratories stock (US0028241000): investors weigh diagnostics strength and medical-device he - AD HOC NEWS

May 26, 2026

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 - PR Newswire

May 26, 2026